(1R,2S)-2-(3-bromophenyl)cyclopropanamine hydrochloride | 1314324-03-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1R,2S)-2-(3-bromophenyl)cyclopropanamine hydrochloride
• 英文别名: 2-(3-bromophenyl)cyclopropanamine HCl；(1R,2S)-2-(3-bromophenyl)cyclopropan-1-amine;hydrochloride
• CAS: 1314324-03-2
• 化学式: C₉H₁₀BrN*ClH
• mdl: MFCD28118779
• 分子量: 248.55
• InChiKey: PDPFGIOAIWJVJE-OULXEKPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.11
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为产物：
  描述：

  3-溴苯乙烯 在 盐酸 、 三乙基硅烷 、 二苯基膦叠氮化物 、 copper(II) bis(trifluoromethanesulfonate) 、 (S,S)-(-)-2,2'-异亚丙基双(4-叔丁基-2-恶唑啉) 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 氯仿 、 乙酸乙酯 为溶剂， 反应 54.5h， 生成 (1R,2S)-2-(3-bromophenyl)cyclopropanamine hydrochloride
  参考文献：
  名称：

  对映体合成作为赖氨酸脱甲基酶（LSD1）抑制剂的tranylcypromine类似物

  摘要：

  通过重氮乙酸叔丁酯对苯乙烯进行不对称环丙烷化，然后进行酯水解和库尔修斯重排，得到了一系列作为单一对映体的反式环丙胺类似物。在LSD1酶分析​​中，o，-m和p-溴类似物的活性均高于反式环丙胺。的米-和p溴类似物是在LNCaP前列腺癌细胞系的微摩尔生长抑制剂作为分别来自溴化物通过Suzuki交叉耦合中制备的对应的联苯类似物。

  DOI：

  10.1016/j.bmc.2011.02.017

文献信息

• Methods and compositions for modulating cancer stem cells
  申请人：University of Canberra

  公开号：US10220053B2

  公开（公告）日：2019-03-05

  Disclosed are compositions and methods that use lysine demethylase inhibitors for inhibiting the growth of cancer stem cells or tumor initiating cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells and/or for preventing cancer recurrence.

  所公开的是使用赖氨酸去甲基化酶抑制剂抑制癌症干细胞或肿瘤始发细胞生长、增强化疗药物或辐照对癌细胞的生物效应和/或预防癌症复发的组合物和方法。
• LYSINE SPECIFIC HISTONE DEMETHYLASE-1 INHIBITORS AND USES THEREFOR
  申请人：University of Canberra

  公开号：EP3509627A1

  公开（公告）日：2019-07-17
• Compositions for Modulating Cancer Stem Cells and Uses Therefor
  申请人：University of Canberra

  公开号：US20170266140A1

  公开（公告）日：2017-09-21

  Disclosed are compositions and methods for modulating cancer stem cells. More particularly, the present invention discloses the use of lysine demethylase (LSD) inhibitors and protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of LSD- and/or PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including non-metastatic and metastatic cancer and/or for preventing cancer recurrence.
• METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS
  申请人：University of Canberra

  公开号：US20190262377A1

  公开（公告）日：2019-08-29

  Disclosed are compositions and methods that use lysine demethylase inhibitors for inhibiting the growth of cancer stem cells or tumor initiating cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells and/or for preventing cancer recurrence.
• ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST
  申请人：EpiAxis Therapeutic Pty Ltd

  公开号：US20210186905A1

  公开（公告）日：2021-06-24

  The present invention relates to a composition for enhancing T-cell function or for treating a T-cell dysfunctional disorder, the composition comprising, consisting or consisting essentially of a lysine specific demethylase (LSD) inhibitor (which may be a MAO inhibitor or phenelzine) and a Programmed cell death protein-1 (PD-1) binding antagonist (which may be an antibody, preferably nivolumab, pembrolizumab, lambrolizumab or pidilizumab).